Meta-Analysis of Ferroptosis Inhibitors for Cisplatin-Induced Kidney Injury

A 2026 meta-analysis by Burcu Yuksel synthesizes preclinical evidence from 58 studies and 265 effect sizes on ferroptosis inhibition in cisplatin-induced acute kidney injury. The document reports pooled standardized mean differences for renal function and ferroptotic biomarkers, including BUN, SCr, GPX4, GSH, MDA, 4-HNE, and Fe2+. It is a 26.9 KB supplementary file shared under a CC-BY-4.0 license.

Use Cases

• Assess the pooled therapeutic effect of ferroptosis inhibitors on renal function based on reported BUN and serum creatinine data.
• Analyze the mechanistic impact of interventions on the antioxidant system based on GPX4 and GSH biomarker results.
• Evaluate evidence for small-study effects and heterogeneity in preclinical research based on the PET-PEESE and Trim and Fill analyses described.

Strengths

• Analysis is based on 58 unique preclinical studies, providing a quantitative synthesis of the field.
• Reports specific pooled effect sizes (Hedges' g) and moderator analysis results for key biomarkers like GPX4 and GSH.
• Follows PRISMA 2020 guidelines for systematic review and uses a three-level random-effects model for meta-analysis.

Limitations

• The dataset is a 26.9 KB document; the underlying tabular meta-analysis data is not directly provided as a structured file.
• Column-level documentation for any extracted data is absent; field semantics must be inferred from the text.
• Row count for the underlying effect size data is unknown, which may limit suitability assessment for direct computational analysis.

Provenance

Source

figshare, author Burcu Yuksel.

Collection Method

Systematic review and multilevel meta-analysis conducted across PubMed and Web of Science.

Freshness

Last updated 2026-05-04 05:33:15.